Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

DOI Web Site Web Site Web Site Web Site 被引用文献5件
  • Yin‐Xiao Du
    Department of Clinical Pharmacology Xiangya Hospital Central South University Changsha Hunan China
  • Xiao‐Ping Chen
    Department of Clinical Pharmacology Xiangya Hospital Central South University Changsha Hunan China

抄録

<jats:p>An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID‐2019. In addition to the recommended antiviral drugs, such as interferon‐ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA‐dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug–drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID‐2019, as data regarding <jats:italic>in vitro</jats:italic> virus inhibition and efficacy in preclinical animal studies are still not available.</jats:p>

収録刊行物

被引用文献 (5)*注記

もっと見る

問題の指摘

ページトップへ